Novartis AG ADR
USUSDNovartis AG ADR (US:NVSEF) — Drug Manufacturers - General. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 4. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte kohta
- Veebileht
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Peakontor
- BASEL, Switzerland
- Tegevjuht
- Dr. Vasant Narasimhan M.D.
- Töötajad
- 75 267
- Asutatud
- 1996
- Ringluses olevad aktsiad
- 1.91 mld seisuga 2025-12-31
- Vabalt kaubeldavad aktsiad
- 1.86 mld
- Turukapitalisatsioon
- 276.48 mld USD
- Siseringi isikud
- 0.01%
- Institutsionaalsed investorid
- 7.27%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- Õiguslik vorm
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Väljamaksesuhe
- 71.1%
- FCF
- 15.0 mld USD61%
- Võlg
- 49.0 mld USD2.6 a FCF
- Dividendistaaž
- 20 a
Kirjeldus
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Dividendid
Novartis AG ADR (NVSEF) maksab dividende ebaregulaarselt. Viimase 12 kuu jooksul maksti 3.7 CHF aktsia kohta (maksed: 1). Makseajaloo põhjal oodatakse järgmist ex-dividendi kuupäeva umbes 11.03.2027. Katkematu dividendiajalugu: 20 aastat.
| Ex-kuupäev | Väljamakse | Summa | % | Tüüp | Tikker |
|---|---|---|---|---|---|
| 2026-03-11 | 2026-03-12 | 3.7000 CHF | 3.3/3.3 % | aastane | US:NVSEF |
Selle nädala uudised
Ettevõtte veebisaidilt uudiseid veel pole.
Suurimad omanikud
| Omanik | Osalus | Aktsiad | Aruande kuupäev |
|---|---|---|---|
| Fisher Asset Management,… | 0.76% | 15.52 mln | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mln | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mln | 2026-06-30 |
| Primecap Management Comp… | 0.32% | 6.59 mln | 2026-06-30 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mln | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mln | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mln | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mln | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mln | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mln | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mln | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mln | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mln | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mln | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mln | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
Järelevalveasutuse sündmused
| Kuupäev | Järelevalveasutus | Sündmus | Üksikasjad |
|---|---|---|---|
| 2026-10-02 | ESMA | оновлення даних інструмента | ISIN, майданчик HAND |